Daniel P. Petrylak, MD
Oncologists looking for options beyond immuno-oncology (I/O) for treating patients with metastatic urothelial carcinoma (mUC) may soon have a range of targeted therapy choices, according to Daniel P. Petrylak, MD.
Petrylak, a professor of medicine and urology at Yale School of Medicine in New Haven, Connecticut, discussed the growing potential for targeted therapies in mUC at the New York GU™: 12th Annual
Interdisciplinary Prostate Cancer Congress®
and Other Genitourinary Malignancies meeting.
In April, the FDA granted an accelerated approval to erdafitinib (Balversa), an oral pan-fibroblast growth factor receptor (FGFR) inhibitor that is the first targeted therapy approved for mUC.
... to read the full story